Drug Trial Radar · NCT04433494
A Study of TY-302 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 7, 2020
Primary completion
May 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: * TY-302 * Tamoxifen
Conditions
- Breast Cancer
- Solid Tumor
Interventions
TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mgDrug
TY-302 is taken orally. Tamoxifen is taken orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302Time frame: 1 year
- Dose Limiting Toxicity (DLT) of TY-302Time frame: First 35 days of dosing
- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302 combine with TamoxifenTime frame: 1 year
- Dose Limiting Toxicity (DLT) of TY-302 combine with TamoxifenTime frame: First 28 days of dosing
- Overall Response Rate (ORR) of TY-302 combine with TamoxifenTime frame: 6 months
- Disease Control Rate(DCR) of TY-302 combine with TamoxifenTime frame: 9 months
- Duration of Response (DOR) of TY-302 combine with TamoxifenTime frame: 9 months
- Progression-free Survival (PFS) of TY-302 combine with TamoxifenTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences and Peking Union Medical Colledge
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.